Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(22)00299-1/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=271757280&_hsenc=p2ANqtz-9WnwpNKFnhtn76gzNFIjaEg-D7kr0TvgIc9sZ1hM9r1I9Acdv8qrHhUm3VgAuhgvPaC-JQN_w_2ASqXCM3-f8nOl99Dg&utm_content=271743104&utm_source=hs_email